PharmaQest Pty Ltd is a private company focussed on drug development, and on drug delivery platforms that overcome pharmacokinetic and toxicokinetic issues. PharmaQest was spun out of the University of South Australia in 2002.
PharmaQest is currently progressing four projects:
The novel topical gel for the chemoprevention of NMSC is the Company’s most advanced project. $2.5m of equity funding was secured, and the Company received an Australian Government Commercial Ready Grant, to develop its lead program.
PharmaQest has expertise in preclinical and clinical drug development, and regulatory applications. The Company’s Board, senior management and US adviser network have international licensing experience.